venture fund, Lilly and Andreessen Horowitz

Spurred by AI’s possibilities, Eli Lilly and Andreessen Horowitz partner on $500M venture fund
Eli Lilly is partnering with the fabled venture capital firm Andreessen Horowitz on a new fund backed with $500 million of the drug giant’s money.
Eli Lilly, Andreessen Horowitz link up on $500M biotech venture fund
Eli Lilly and venture capital firm Andreessen Horowitz (a16z) are joining forces to create a unique new fund dubbed the Biotech Ecosystem Venture Fund, backed by $500 million of Lilly’s capital.
Lilly Partners With a16z on $500M VC Fund for Early-Stage Biotechs
The Biotech Ecosystem Venture Fund will combine the sourcing capabilities of venture capital firm Andreessen Horowitz (a16z) with Eli Lilly’s expertise in R&D—plus half a billion in capital from the Big Pharma.
Andreessen Horowitz, Eli Lilly to launch $500 million venture fund
Venture capital firm Andreessen Horowitz said on Friday it was working with Eli Lilly to launch a $500 million venture fund that will be fully funded by the U.S. drugmaker. WHY IT'S IMPORTANT The fund,
Andreessen Horowitz Partners with Lilly to Launch First-of-Its-Kind Biotech Ecosystem Venture Fund
Bio + Health today announced a newly formed, first-of-its-kind venture capital fund to fuel broader innovation in human health, in partnership with Eli Lilly and Company ("Lilly"). The Biotech Ecosystem Venture Fund ("Fund") seeks to drive transformative progress in healthcare by investing in therapeutic platforms and cutting-edge technology companies that can bring new medicines and disease treatments to improve patients' lives.
Eli Lilly in talks to acquire Scorpion Therapeutics, FT says; Relay Therapeutics seesaws
Eli Lilly (NYSE:LLY) is in advanced discussions to purchase cancer-focused biotech Scorpion Therapeutics for as much as $2.5 ...
Eli Lilly in advanced talks to buy US cancer biotech for up to $2.5bn
Scorpion’s drug candidate inhibits a mutation that is a major driver of breast, gynaecological and head and neck cancers ...
BioSpace8h
Lilly Makes $780M+ IPF Play with Mediar Partnership
Eli Lilly’s idiopathic pulmonary fibrosis deal with Mediar is centered around MTX-463, an anti-WISP1 antibody that early ...
Eli Lilly's Zepbound Can Now Be Covered by Medicare to Treat Sleep Apnea
Key Takeaways Eli Lilly's Zepbound can be covered by Medicare Part D plans after the FDA approved the drug as a treatment for ...
FiercePharma6h
Lilly doubles down on its presence in India with new capability center, plans to hire 1,000+
Eli Lilly has been operating a global capability center (GCC) in Bengaluru, India. | For nearly a decade, Eli Lilly has been operating a global capability center (GCC) in Bengaluru, India. Now, with ...
Eli Lilly setting up GCC in Hyderabad, to hire over 1,000 people
Eli Lilly & Company to establish new global capability centre in Hyderabad, recruiting over 1,000 professionals for advanced ...
Medicare can now cover Eli Lilly's Zepbound for sleep apnea, CMS says
It opens the door for broader coverage and access to Zepbound, which is not currently covered by Medicare and many other ...
Is Eli Lilly Stock a Buy?
Eli Lilly's stock has been a strong winner over the past few years, powered by its portfolio of glucagon-like peptide-1 ...
Eli Lilly and Company to set-up global capability centre in Hyderabad, to recruit over 1,000 skilled workers
The company said that it would be recruiting more than a 1,000 highly-skilled team members to strengthen its digital strategy ...
FierceBiotech9h
Eli Lilly pushes into pulmonary fibrosis with $99M deal for Mediar's midphase prospect
Eli Lilly is making a play for the idiopathic pulmonary fibrosis (IPF) market, offering Mediar Therapeutics $99 million in ...